Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.78 USD | +0.78% | -1.34% | -32.50% |
09/05 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
09/05 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.50% | 936M | |
+25.97% | 49.18B | |
+0.60% | 42.11B | |
+50.01% | 40.37B | |
-5.26% | 28.85B | |
+13.28% | 26.09B | |
-21.95% | 18.71B | |
+8.40% | 13.26B | |
+31.95% | 12.32B | |
-0.10% | 11.99B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Viridian Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight